<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01072344</url>
  </required_header>
  <id_info>
    <org_study_id>AT005074</org_study_id>
    <nct_id>NCT01072344</nct_id>
  </id_info>
  <brief_title>Long Term Chamomile Therapy for Anxiety</brief_title>
  <official_title>Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prior research has shown that chamomile may be an effective, short-term anti-anxiety&#xD;
      treatment. This study will examine the initial and long-term benefits of chamomile extract&#xD;
      therapy for the prevention of recurrent anxiety disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anxiety disorders are among the most common psychiatric conditions. They affect up to 25% of&#xD;
      the US adult population. Generalized anxiety disorder (GAD) is a chronic, recurrent form of&#xD;
      the disorder. Although benzodiazepines and serotonin reuptake inhibitors have become the&#xD;
      mainstay therapy of GAD, these drugs are often associated with unwanted side effects,&#xD;
      habituation, and withdrawal symptoms. Many individuals decline using conventional drug&#xD;
      therapy for financial, cultural, or personal reasons such as the stigma of mental illness. As&#xD;
      a result, many individuals will seek alternative therapy for their anxiety symptoms. The&#xD;
      identification of effective alternative therapies for GAD would be of particular relevance.&#xD;
      Among alternative therapies for anxiety, chamomile has been used as a traditional herbal&#xD;
      medicine for its calming effect. It is well tolerated and demonstrates pharmacological&#xD;
      activity in animal models of anxiety. Despite its widespread use and availability, there has&#xD;
      been only one clinical trial of chamomile safety and efficacy in GAD. The current application&#xD;
      seeks to build upon the results of that prior chamomile study. In that 8-week, double-blind,&#xD;
      placebo-controlled trial, we found a significant superiority of chamomile (vs. placebo) in&#xD;
      reducing GAD symptoms. We also found chamomile to be exceedingly well tolerated (vs.&#xD;
      placebo). The current application seeks to extend these promising preliminary results by&#xD;
      conducting a randomized, double-blind, parallel group, placebo-substitution, long-term safety&#xD;
      and efficacy study of chamomile in preventing GAD relapse. For specific aim #1 we will ask:&#xD;
      &quot;Does long-term chamomile therapy (vs. placebo) prolong the time to relapse of anxiety&#xD;
      symptoms following recovery from GAD?&quot; To answer this question, 180 patients with moderate to&#xD;
      severe GAD will receive open-label chamomile extract 500-1,500 mg daily for 8 weeks.&#xD;
      Responders to chamomile, who remain well for 4 additional weeks of consolidation therapy,&#xD;
      will be randomized to double-blind continuation therapy with chamomile 500-1,500 mg daily or&#xD;
      placebo for an additional 26 weeks. We hypothesize that continuation chamomile therapy will&#xD;
      result in a prolonged time to relapse (vs. placebo). For specific aim #2 we will ask: &quot;What&#xD;
      is the relative safety and tolerability of long-term chamomile therapy (vs. placebo) in&#xD;
      patients who have recovered from GAD?&quot; To answer this question, we will examine the following&#xD;
      outcome measures: (i) the proportion of patients in each treatment condition who relapse;&#xD;
      (ii) the frequency, severity, and duration of treatment-emergent adverse events; (iii) the&#xD;
      frequency of discontinuation symptoms during initial double-blind therapy; and, (iv) the&#xD;
      frequency of early study discontinuation. We hypothesize that chamomile therapy will result&#xD;
      in a lower proportion of anxiety relapses and a lower study discontinuation rate (vs.&#xD;
      placebo). We further hypothesize that chamomile therapy will result in a similar frequency of&#xD;
      discontinuation symptoms and treatment-emergent adverse events (vs. placebo).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Relapse in Each Treatment Condition.</measure>
    <time_frame>26 weeks</time_frame>
    <description>The primary outcome was time to relapse during continuation therapy, analyzed using Cox proportional hazards. Relapse is dichotomously defined as an increase in CGI/S (a clinician-rated global measure of anxiety's severity) score from ≤ 3 (at study visit 6) to ≥ 4 (on two consecutive scheduled or unscheduled study visits ≥ 2 weeks apart) plus meeting DSM IV-TR criteria for GAD (minus the 6-month time criterion).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Subjects in Each Treatment Condition Who Relapse.</measure>
    <time_frame>26 weeks</time_frame>
    <description>The proportion of subjects in each treatment condition who relapsed after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, Severity, and Duration of Treatment-emergent Adverse Events.</measure>
    <time_frame>26 weeks</time_frame>
    <description>We will report the frequency, severity, and duration of treatment-emergent adverse events by treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Discontinuation Symptoms at the Start of Double-blind Therapy in Each Treatment Condition.</measure>
    <time_frame>26 weeks</time_frame>
    <description>Discontinuation emergent signs and symptoms checklist (DESS) is a patient-rated measure of the presence and severity of discontinuation symptoms occurring after medication discontinuation. %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Early Study Discontinuation in Each Treatment Condition.</measure>
    <time_frame>26 weeks</time_frame>
    <description>This is the # of subjects who discontinued the study during randomization phase due to other reasons.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Chamomile Extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmaceutical grade oral chamomile extract.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pharmaceutical grade lactose monohydrate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chamomile (Matricaria recutita)</intervention_name>
    <description>500 mg 3 times daily</description>
    <arm_group_label>Chamomile Extract</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Chamomile</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women at least 18 years old (all races and ethnicity)&#xD;
&#xD;
          -  DSM IV diagnosis of GAD as the primary anxiety disorder&#xD;
&#xD;
          -  Baseline GAD-7 score ≥ 10&#xD;
&#xD;
          -  Baseline CGI/S score at least 4&#xD;
&#xD;
          -  Not taking anti-anxiety medication (e.g., Benzodiazepines, buspirone, antidepressants)&#xD;
&#xD;
          -  Not taking antidepressant, mood stabilizer, or tranquilizer therapy for a prior DSM IV&#xD;
             Axis I mood disorder that is in remission&#xD;
&#xD;
          -  Able to understand and provide informed consent&#xD;
&#xD;
          -  Able to participate in a 38-week study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients &lt; 18 years old&#xD;
&#xD;
          -  Primary DSM IV Axis I anxiety disorder other than GAD (e.g., panic disorder with or&#xD;
             without agoraphobia, phobia disorder, acute stress disorder, social anxiety disorder,&#xD;
             obsessive-compulsive disorder, post-traumatic stress disorder, substance-induced&#xD;
             anxiety disorder)&#xD;
&#xD;
          -  Current DSM IV Axis I psychotic disorder&#xD;
&#xD;
          -  Substance abuse or dependence within the prior 3 months&#xD;
&#xD;
          -  Current DSM IV Axis I bipolar or major depressive disorder [Note: Patients with&#xD;
             co-morbid depressive disorder NOS (e.g., minor depression, recurrent brief depressive&#xD;
             disorder, or premenstrual dysphoric disorder (PMDD)] will not be excluded&#xD;
&#xD;
          -  Unstable medical condition&#xD;
&#xD;
          -  Allergy to chamomile&#xD;
&#xD;
          -  Documented allergy to plants of the asteraceae family (e.g., ragweed, asters,&#xD;
             chrysanthemum)&#xD;
&#xD;
          -  Allergic to mugwort or birch pollen&#xD;
&#xD;
          -  Concurrent anti-anxiety tranquilizer, antidepressant or mood stabilizer therapy&#xD;
&#xD;
          -  Concurrent use of over-the-counter anti-anxiety and/or antidepressant preparations&#xD;
             (e.g., chamomile, St. John's Wort, kava kava)&#xD;
&#xD;
          -  Concurrent use of established antidepressant, mood stabilizer, or tranquilizer therapy&#xD;
             for pre-existing affective disorder. [Note: Patients with a history of affective&#xD;
             disorder (in remission) who are not currently taking antidepressant, mood stabilizer,&#xD;
             or tranquilizer therapy are not excluded from the trial]&#xD;
&#xD;
          -  Women of child-bearing potential not willing to use a medically proven form of&#xD;
             contraception&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Actively suicidal or suicide attempt within the preceding 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun J Mao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Depression Research Unit</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-3309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2010</study_first_posted>
  <results_first_submitted>April 28, 2017</results_first_submitted>
  <results_first_submitted_qc>June 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 6, 2017</results_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anxiety</keyword>
  <keyword>Chamomile</keyword>
  <keyword>Herbal Remedy</keyword>
  <keyword>Complementary and Alternative Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study has 3 phases. The 1st phase is open label cham.(N=179), subjects meeting response criteria enter 2nd phase (N=93), the consolidation phase of open label chamomile. At the end of 2nd phase, if subjects still meet response criteria, they will enter the 3rd phase (N=93). In the 3rd phase, subjects will be randomized to chamomile vs. placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Chamomile Extract</title>
          <description>Pharmaceutical grade oral chamomile extract.&#xD;
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Pharmaceutical grade lactose monohydrate.&#xD;
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Relasped-reached end point</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chamomile Extract</title>
          <description>Pharmaceutical grade oral chamomile extract.&#xD;
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Pharmaceutical grade lactose monohydrate.&#xD;
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="93"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.2" spread="14.3"/>
                    <measurement group_id="B2" value="45.4" spread="16.1"/>
                    <measurement group_id="B3" value="47.3" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Relapse in Each Treatment Condition.</title>
        <description>The primary outcome was time to relapse during continuation therapy, analyzed using Cox proportional hazards. Relapse is dichotomously defined as an increase in CGI/S (a clinician-rated global measure of anxiety's severity) score from ≤ 3 (at study visit 6) to ≥ 4 (on two consecutive scheduled or unscheduled study visits ≥ 2 weeks apart) plus meeting DSM IV-TR criteria for GAD (minus the 6-month time criterion).</description>
        <time_frame>26 weeks</time_frame>
        <population>All 93 subjects started randomization phase of the study were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Chamomile Extract</title>
            <description>Pharmaceutical grade oral chamomile extract.&#xD;
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Pharmaceutical grade lactose monohydrate.&#xD;
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Relapse in Each Treatment Condition.</title>
          <description>The primary outcome was time to relapse during continuation therapy, analyzed using Cox proportional hazards. Relapse is dichotomously defined as an increase in CGI/S (a clinician-rated global measure of anxiety's severity) score from ≤ 3 (at study visit 6) to ≥ 4 (on two consecutive scheduled or unscheduled study visits ≥ 2 weeks apart) plus meeting DSM IV-TR criteria for GAD (minus the 6-month time criterion).</description>
          <population>All 93 subjects started randomization phase of the study were included in the analysis</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="8.4"/>
                    <measurement group_id="O2" value="6.3" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Subjects in Each Treatment Condition Who Relapse.</title>
        <description>The proportion of subjects in each treatment condition who relapsed after randomization</description>
        <time_frame>26 weeks</time_frame>
        <population>During phase II consolidation phase, treatment responders were randomized to either 26 weeks of continuation chamomile therapy or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Chamomile Extract</title>
            <description>Pharmaceutical grade oral chamomile extract.&#xD;
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Pharmaceutical grade lactose monohydrate.&#xD;
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Subjects in Each Treatment Condition Who Relapse.</title>
          <description>The proportion of subjects in each treatment condition who relapsed after randomization</description>
          <population>During phase II consolidation phase, treatment responders were randomized to either 26 weeks of continuation chamomile therapy or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency, Severity, and Duration of Treatment-emergent Adverse Events.</title>
        <description>We will report the frequency, severity, and duration of treatment-emergent adverse events by treatment arm.</description>
        <time_frame>26 weeks</time_frame>
        <population>During phase II consolidation phase, treatment responders were randomized to either 26 weeks of continuation chamomile therapy or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Chamomile Extract</title>
            <description>Pharmaceutical grade oral chamomile extract.&#xD;
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Pharmaceutical grade lactose monohydrate.&#xD;
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency, Severity, and Duration of Treatment-emergent Adverse Events.</title>
          <description>We will report the frequency, severity, and duration of treatment-emergent adverse events by treatment arm.</description>
          <population>During phase II consolidation phase, treatment responders were randomized to either 26 weeks of continuation chamomile therapy or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Discontinuation Symptoms at the Start of Double-blind Therapy in Each Treatment Condition.</title>
        <description>Discontinuation emergent signs and symptoms checklist (DESS) is a patient-rated measure of the presence and severity of discontinuation symptoms occurring after medication discontinuation. %</description>
        <time_frame>26 weeks</time_frame>
        <population>These are responders at the end of Phase II of the study and then were randomized in Phase III of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Chamomile Extract</title>
            <description>Pharmaceutical grade oral chamomile extract.&#xD;
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Pharmaceutical grade lactose monohydrate.&#xD;
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Discontinuation Symptoms at the Start of Double-blind Therapy in Each Treatment Condition.</title>
          <description>Discontinuation emergent signs and symptoms checklist (DESS) is a patient-rated measure of the presence and severity of discontinuation symptoms occurring after medication discontinuation. %</description>
          <population>These are responders at the end of Phase II of the study and then were randomized in Phase III of the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># of subject had no new symptoms after randomizat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of subject had &gt;=1 new symptom after randomizati</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Early Study Discontinuation in Each Treatment Condition.</title>
        <description>This is the # of subjects who discontinued the study during randomization phase due to other reasons.</description>
        <time_frame>26 weeks</time_frame>
        <population>These are responders at the end of Phase II of the study and were then randomized into Phase III of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Chamomile Extract</title>
            <description>Pharmaceutical grade oral chamomile extract.&#xD;
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Pharmaceutical grade lactose monohydrate.&#xD;
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Early Study Discontinuation in Each Treatment Condition.</title>
          <description>This is the # of subjects who discontinued the study during randomization phase due to other reasons.</description>
          <population>These are responders at the end of Phase II of the study and were then randomized into Phase III of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># Lost to Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># withdrawn due to non-compliance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Chamomile Extract</title>
          <description>Pharmaceutical grade oral chamomile extract.&#xD;
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Pharmaceutical grade lactose monohydrate.&#xD;
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased platelet count</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ringing in ears</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Herbal taste</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sleep paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>taste perversion</sub_title>
                <description>taste perversion caused by strong chamomile smell</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jun Mao</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-888-0866</phone>
      <email>maoj@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

